BACILIERI, MAGDALENA
 Distribuzione geografica
Continente #
NA - Nord America 1.142
AS - Asia 164
EU - Europa 110
SA - Sud America 4
Totale 1.420
Nazione #
US - Stati Uniti d'America 1.142
SG - Singapore 81
CN - Cina 66
FI - Finlandia 26
DE - Germania 21
FR - Francia 17
IT - Italia 14
UA - Ucraina 13
VN - Vietnam 13
IE - Irlanda 7
GB - Regno Unito 6
BR - Brasile 4
SE - Svezia 4
TR - Turchia 4
SI - Slovenia 2
Totale 1.420
Città #
Fairfield 197
Woodbridge 109
Chandler 86
Houston 84
Santa Clara 79
Cambridge 74
Singapore 71
Jacksonville 67
Wilmington 66
Seattle 58
Ashburn 55
Princeton 33
Ann Arbor 30
Boardman 23
Des Moines 23
San Diego 19
Dong Ket 13
Columbus 9
Helsinki 9
Nanjing 9
Beijing 8
Dublin 7
Falls Church 6
Tianjin 6
Medford 5
Padova 5
Nanchang 4
Treviso 4
Yenibosna 4
Hebei 3
Jinan 3
Munich 3
Shenyang 3
Americana 2
Changsha 2
Kharkiv 2
Ljubljana 2
Marseille 2
Ogden 2
São Paulo 2
Telgate 2
Guangzhou 1
Hangzhou 1
Hounslow 1
Indiana 1
Kilburn 1
Lappeenranta 1
London 1
Ningbo 1
Norwalk 1
Pontinia 1
Portland 1
Prescot 1
Qingdao 1
Rockville 1
Totale 1.205
Nome #
Combining ligand-based and structure-based drug design in the virtual screening arena 127
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure -activity profile. 120
A Novel Generalized 3D-QSAR Model of Camptothecin Analogs 114
G protein-coupled receptors as challenging druggable targets: insights from in silico studies 108
Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: Design of new Gly/NMDA receptor antagonists as a key study 104
Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity 94
Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update 88
Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the Activity of Human A3 Adenosine Receptor Antagonists. 86
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2AAdenosine Receptor Antagonists 86
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 82
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A(2A) receptor 77
Fit-For-Purpose PD-L1 Biomarker Testing for Patient Selection in Immuno-Oncology: Guidelines for Clinical Laboratories from the Canadian Association of Pathologists-Association Canadienne des Pathologistes (CAP-ACP) 69
Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-beta 1 expression in mesangial cells: biochemical and structural considerations 61
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: a novel tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 58
Prediction of the acqueous solvation free energy of organic compounds by using autocorrelation of molecular electrostatic potential surface properties combined with response surface analysis 57
The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: Application to a lead optimization of a human A(3) adenosine receptor antagonist 56
Response Surface Analysis as aternative 3D-QSAR tool: human A3 adenosine receptor antagonists as a key study. 37
Totale 1.424
Categoria #
all - tutte 5.717
article - articoli 5.717
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.434


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020139 0 0 0 0 0 18 24 29 25 20 14 9
2020/2021176 11 6 5 18 8 31 0 9 33 13 25 17
2021/2022257 12 37 32 20 4 11 18 28 5 8 33 49
2022/2023197 36 7 0 18 33 55 0 14 25 0 7 2
2023/202486 4 14 16 9 9 1 9 7 2 1 7 7
2024/2025222 0 75 18 27 87 15 0 0 0 0 0 0
Totale 1.424